7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVAL

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          While gene expression profiling is commonly used to gain an overview of cellular processes, the identification of upstream processes that drive expression changes remains a challenge. To address this issue, we introduce CARNIVAL, a causal network contextualization tool which derives network architectures from gene expression footprints. CARNIVAL (CAusal Reasoning pipeline for Network identification using Integer VALue programming) integrates different sources of prior knowledge including signed and directed protein–protein interactions, transcription factor targets, and pathway signatures. The use of prior knowledge in CARNIVAL enables capturing a broad set of upstream cellular processes and regulators, leading to a higher accuracy when benchmarked against related tools. Implementation as an integer linear programming (ILP) problem guarantees efficient computation. As a case study, we applied CARNIVAL to contextualize signaling networks from gene expression data in IgA nephropathy (IgAN), a condition that can lead to chronic kidney disease. CARNIVAL identified specific signaling pathways and associated mediators dysregulated in IgAN including Wnt and TGF-β, which we subsequently validated experimentally. These results demonstrated how CARNIVAL generates hypotheses on potential upstream alterations that propagate through signaling networks, providing insights into diseases.

          Network inference: causal reasoning from expression and prior knowledge

          Changes in gene expression are generally indirect consequences of upstream dysregulation, and it is often important to understand what caused it. A team of researchers led by Julio Saez-Rodriguez from Heidelberg and Aachen has developed CARNIVAL to infer causal networks of proteins upstream of gene expression. In the first step, dysregulated transcription factors are inferred from gene expression. Subsequently, an algorithm finds explanations for their up- or down-regulation through known protein–protein interactions using an ILP formulation. Optionally, known targets of perturbation can be provided. This integration of different sources of prior knowledge led to higher performance than alternative methods and was able to identify key pathways and proteins, including TGFβ signaling and β-Catenin, in a case study on IgA nephropathy. Overall, CARNIVAL may provide clues to understand causal mechanisms in diseases and treatments.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Oncogenic pathway signatures in human cancers as a guide to targeted therapies.

          The development of an oncogenic state is a complex process involving the accumulation of multiple independent mutations that lead to deregulation of cell signalling pathways central to the control of cell growth and cell fate. The ability to define cancer subtypes, recurrence of disease and response to specific therapies using DNA microarray-based gene expression signatures has been demonstrated in multiple studies. Various studies have also demonstrated the potential for using gene expression profiles for the analysis of oncogenic pathways. Here we show that gene expression signatures can be identified that reflect the activation status of several oncogenic pathways. When evaluated in several large collections of human cancers, these gene expression signatures identify patterns of pathway deregulation in tumours and clinically relevant associations with disease outcomes. Combining signature-based predictions across several pathways identifies coordinated patterns of pathway deregulation that distinguish between specific cancers and tumour subtypes. Clustering tumours based on pathway signatures further defines prognosis in respective patient subsets, demonstrating that patterns of oncogenic pathway deregulation underlie the development of the oncogenic phenotype and reflect the biology and outcome of specific cancers. Predictions of pathway deregulation in cancer cell lines are also shown to predict the sensitivity to therapeutic agents that target components of the pathway. Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Transcriptome Analysis of Human Diabetic Kidney Disease

            OBJECTIVE Diabetic kidney disease (DKD) is the single leading cause of kidney failure in the U.S., for which a cure has not yet been found. The aim of our study was to provide an unbiased catalog of gene-expression changes in human diabetic kidney biopsy samples. RESEARCH DESIGN AND METHODS Affymetrix expression arrays were used to identify differentially regulated transcripts in 44 microdissected human kidney samples. DKD samples were significant for their racial diversity and decreased glomerular filtration rate (~25–35 mL/min). Stringent statistical analysis, using the Benjamini-Hochberg corrected two-tailed t test, was used to identify differentially expressed transcripts in control and diseased glomeruli and tubuli. Two different web-based algorithms were used to define differentially regulated pathways. RESULTS We identified 1,700 differentially expressed probesets in DKD glomeruli and 1,831 in diabetic tubuli, and 330 probesets were commonly differentially expressed in both compartments. Pathway analysis highlighted the regulation of Ras homolog gene family member A, Cdc42, integrin, integrin-linked kinase, and vascular endothelial growth factor signaling in DKD glomeruli. The tubulointerstitial compartment showed strong enrichment for inflammation-related pathways. The canonical complement signaling pathway was determined to be statistically differentially regulated in both DKD glomeruli and tubuli and was associated with increased glomerulosclerosis even in a different set of DKD samples. CONCLUSIONS Our studies have cataloged gene-expression regulation and identified multiple novel genes and pathways that may play a role in the pathogenesis of DKD or could serve as biomarkers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Perturbation-response genes reveal signaling footprints in cancer gene expression

              Aberrant cell signaling can cause cancer and other diseases and is a focal point of drug research. A common approach is to infer signaling activity of pathways from gene expression. However, mapping gene expression to pathway components disregards the effect of post-translational modifications, and downstream signatures represent very specific experimental conditions. Here we present PROGENy, a method that overcomes both limitations by leveraging a large compendium of publicly available perturbation experiments to yield a common core of Pathway RespOnsive GENes. Unlike pathway mapping methods, PROGENy can (i) recover the effect of known driver mutations, (ii) provide or improve strong markers for drug indications, and (iii) distinguish between oncogenic and tumor suppressor pathways for patient survival. Collectively, these results show that PROGENy accurately infers pathway activity from gene expression in a wide range of conditions.
                Bookmark

                Author and article information

                Contributors
                julio.saez@bioquant.uni-heidelberg.de
                Journal
                NPJ Syst Biol Appl
                NPJ Syst Biol Appl
                NPJ Systems Biology and Applications
                Nature Publishing Group UK (London )
                2056-7189
                11 November 2019
                11 November 2019
                2019
                : 5
                : 40
                Affiliations
                [1 ]Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany
                [2 ]ISNI 0000 0001 0728 696X, GRID grid.1957.a, RWTH Aachen University, Faculty of Medicine, Joint Research Centre for Computational Biomedicine (JRC-COMBINE), ; 52074 Aachen, Germany
                [3 ]ISNI 0000 0004 1936 8411, GRID grid.9918.9, Department of Infection, Immunity and Inflammation, , University of Leicester, ; Leicester, UK
                Author information
                http://orcid.org/0000-0001-9015-5855
                http://orcid.org/0000-0001-8042-0395
                http://orcid.org/0000-0002-8552-8976
                Article
                118
                10.1038/s41540-019-0118-z
                6848167
                31728204
                cf9d3127-186e-4957-b6a3-533bf4131431
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 12 June 2019
                : 9 October 2019
                Funding
                Funded by: Innovative Medicines Initiative 2 Joint Undertaking "TransQST" (116030)
                Funded by: European Union's Horizon 2020 program "Marie-Curie ITN" (675585)
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                regulatory networks,software
                regulatory networks, software

                Comments

                Comment on this article

                scite_

                Similar content146

                Cited by46

                Most referenced authors1,173